PLK1 and non-small cell lung carcinoma: The observed overexpression of Plk1 in several human malignancies, including non‐small‐cell lung cancer (NSCLC), and its correlation with poor patient prognosis has led to the development of various small‐molecule inhibitors against Plk1 (Li et al., 2017; Strebhardt and Ullrich, 2006; Van den Bossche et al., 2017; Wang et al., 2012).